In the prevailing economic environment where people are finding it difficult to survive the impending crisis, companies which provide the lowest rates as well as innovative products tend to win. Though there is a section of people who don�� mind splurging on branded products at any point of time, there is a large section of customers who are greatly influenced by price and promotions.
This is what is understood and followed continuously by the packaged food retailer ConAgra Foods (CAG). The company has been performing well, owing to its expansion in the low priced private label products which are faring well since it is lighter on consumers��pockets. However, unfavorable weather conditions forced the food company to register a dull quarter. Let us understand the company better.
Driven By Acquisitions
ConAgra�� keenness of expanding its consumer products segment through a host of acquisitions has been instrumental to its success. However, lower store traffic led to 3% decline in revenue to $4.44 billion. The consumer foods segment declined 7% over last year because of lower volumes. However, the commercial food segment did well with a 1% rise in revenue mainly due to products such as bakery products, specialty potato and private label food products.
Top 5 Casino Companies For 2015: Ameresco Inc (AMRC)
Ameresco, Inc. incorporated in April 2000, is a provider of energy efficiency solutions for facilities throughout North America. The Company�� services include upgrades to a facility's energy infrastructure and the construction and operation of small-scale renewable energy plants. Its principal service is the development, design, engineering and installation of projects that reduce the energy and operations and maintenance (O&M) costs of its customers' facilities. These projects include a variety of measures customized for the facility and designed to improve the efficiency of major building systems, such as heating, ventilation, air conditioning and lighting systems. It also serves certain customers by developing and building small-scale renewable energy plants located at or close to a customer's site. Ameresco, Inc. provides its services primarily to governmental, educational, utility, healthcare and other institutional, commercial and industrial entities. The Company operates in four segments: U.S. federal, central U.S. region, other U.S. regions and Canada. In August 2011, the Company acquired APS Energy Services Company, Inc. from Pinnacle West Capital Corporation. In December 2011, it acquired the xChange Point and energy projects businesses, including automated demand response, of Energy and Power Solutions, Inc. In August 2012, the Company acquired FAME Facility Software Solutions Inc. In February 2013, it purchased all of the assets of Ennovate Corporation. In June 2013, Ameresco Inc acquired ESP, an energy management consulting company consisting of the Energy Services Partnership and ESP Response, located in Castleford, United Kingdom.
Ameresco, Inc. offers a set of services that includes the design and installation of upgrades to a facility�� energy infrastructure, the design and construction of renewable energy plants, the sale of other renewable energy products and the arranging of financing for customer projects. In September 2010, the Company acquired Quantum Engineer! ing and Development, Inc. In July 2011, the Company acquired Applied Energy Group.
Energy Efficiency Services
The Company�� services includes the design, engineering and installation of, and the arranging of financing for, equipment to improve the efficiency, and control the operation, of a building�� heating, ventilation, cooling and lighting systems. In certain projects, it also designs and constructs a central plant or cogeneration system providing power, heat and/or cooling to a building. Its projects generally range in size and scope from a one-month project to design and retrofit a lighting system to a more complex 30-month project to design and install a central plant or cogeneration system.
Renewable Energy Projects and Products
The Company�� services offering includes the development, construction and operation of, and the arrangement of financing for, small-scale renewable energy plants, as well as the sale and integration of solar energy products and systems. It has constructed and is designing and constructing a range of renewable energy plants using landfill gas (LFG), wastewater treatment biogas, solar, wind, biomass, food waste, animal waste and hydro sources of energy. As part of its renewable energy offering, it also distributes and integrates solar energy products manufactured by several vendors. Ameresco, Inc. is a distributor of photovoltaic (PV) panels, solar regulators, solar charge controllers, inverters, solar powered lighting systems, solar powered water pumps, solar panel mounting hardware and other system components. It also integrates its PV products and system components into solar solutions designed specifically for customers. It provides solar energy solutions for both on- grid applications where the solar power is used in a building connected to a utility distribution system, and for off-grid applications where the power is used directly in the device using the electricity, such as traffic signs.
Amere! sco, Inc.! also designs and constructs renewable energy plants based on wind power. In many parts of the country, available wind resources, utility net metering and local incentives can make on-site wind generation a viable solution for meeting a portion of customers' energy needs. As of December 31, 2010, the Company had completed two projects that included a wind turbine. In addition, it has constructed and was constructing, small-scale renewable energy plants based on biomass.
As of December 31, 2010, Ameresco, Inc. had constructed more than 28 renewable energy projects, and owned and operated 22 small-scale renewable energy plants. Of the owned plants, 19 are renewable LFG plants, two are waste water biogas plants and one is a solar PV installation. These 22 small-scale renewable energy plants have the capacity to generate electricity or deliver LFG producing an aggregate of 106 megawatts (MW) or megawatt-equivalents (MWE). As of December 31, 2010, the Company had signed contracts for the construction, operation and ownership of an additional six LFG plants, two biomass power and cogeneration plants and five biomass boiler projects.
The Company competes with Chevron Energy Solutions, Constellation Energy, Honeywell, Johnson Controls, Siemens Building Technologies and TAC Energy Solutions.
Advisors' Opinion:- [By Sara Murphy]
Ameresco (NYSE: AMRC ) is one of the few large, independent energy efficiency service providers. The company's principal service is the development, design, engineering and installation of projects that reduce the energy and operations and maintenance costs of its customers' facilities. Ameresco has seen declining revenues recently because of unusually long lag times in getting its projects funded, but this seems a temporary setback.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, energy efficiency technologist Ameresco (NYSE: AMRC ) has earned a coveted five-star ranking.
10 Best Low Price Stocks To Buy For 2014: EMCORE Corporation(EMKR)
EMCORE Corporation, together with its subsidiaries, provides compound semiconductor-based products for the broadband, fiber optics, satellite, and solar power markets. The company operates in two segments, Fiber Optics and Photovoltaics. The Fiber Optics segment offers broadband products, including cable television, fiber-to-the-premises, satellite communication, video transport, and defense and homeland security products; and digital products comprising telecom optical, enterprise, laser/photodetector component, parallel optical transceiver and cable, and fiber channel transceiver products. This segment?s products enable information that is encoded on light signals to be transmitted, routed, and received in communication systems and networks. The Photovoltaics segment provides gallium arsenide (GaAs) multi-junction solar cells, covered interconnected cells, and solar panels for satellite applications; and concentrating photovoltaic (CPV) power systems for commercial and utility scale solar applications, as well as GaAs solar cells and integrated CPV components for use in other solar power concentrator systems. The company markets its products through its direct sales force, external sales representatives and distributors, and application engineers worldwide. EMCORE Corporation was founded in 1984 and is headquartered in Albuquerque, New Mexico.
Advisors' Opinion:- [By CRWE]
EMCORE Corporation (Nasdaq:EMKR), a leading provider of compound semiconductor-based components and subsystems for the fiber optic and solar power markets, reported that it is ramping production and shipping the Opticomm-EMCORE NEXTGEN OTP-1DVI2A1SU insert cards for the Optiva platform.
10 Best Low Price Stocks To Buy For 2014: Eco Depot Inc (ECDP)
Eco Depot, Inc. (Eco Depot), incorporated on November 2, 2004, is a development-stage company. The Company is in the business of developing an Internet e-commerce Website that will sell a range of environmentally friendly goods, energy efficient building and construction materials and sustainable home products. Eco Depot will not manufacture any equipment or goods, but will resell green products from various manufacturers. In July 2010, Eco Depot Inc acquired CS Tech (America).
Eco Depot, Inc. plans to develop and market an e-commerce enabled Website, which would attract prospective industrial clientele, businesses, municipalities and individual customers seeking cleaner technologies and products. The Company plans to market and sell through its Website goods and products that are defined as green. These green products include recycled paper counter tops, environmentally friendly paints, and recycled glass tiles. Eco Depot began the initial development of its Website (www.ecodepotinc.com.) where these products are listed.
Advisors' Opinion:- [By Peter Graham]
Small cap green stocks Eco Depot Inc (OTCMKTS: ECDP), Eco Building Products Inc (OTCMKTS: ECOB) and Profire Energy, Inc (OTCBB: PFIE) has been getting some extra attention lately in various investment newsletters thanks to paid promotions or investor relation campaigns. Of course, there is nothing wrong with properly disclosed promotions and investor relations campaigns, but small cap green stocks tend to be extra volatile when compared with other stocks. So how in greenbacks will these three small cap green stocks produce for investors? Here is a quick reality check:
10 Best Low Price Stocks To Buy For 2014: Genomic Health Inc (GHDX)
Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.
Oncotype DX Platform
The Company�� Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient'! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.
Oncotype DX Breast Cancer Test
To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.
In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.
Oncotype DX Colon Cancer Test
The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and recurrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.
The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.
Advisors' Opinion:- [By Jon C. Ogg]
Genomic Health Inc. (NASDAQ: GHDX) was downgraded to Underperform from an already cautious Neutral and the price target was cut to $33 from $36 by Bank of America�Merrill Lynch.
10 Best Low Price Stocks To Buy For 2014: Elbit Systems Ltd. (ESLT)
Elbit Systems Ltd. engages in the design, development, manufacture, and integration of defense systems and products worldwide. The company operates in the areas of aerospace, land and naval systems, command, control, communications, computers, intelligence, surveillance and reconnaissance, unmanned aircraft systems, advanced electro-optics, electro-optic space systems, electronic warfare (EW) suites, airborne warning systems, electronic intelligence systems, data links, artillery systems, military communications systems, and radios. Its activities include military aircraft and helicopter systems, helmet mounted systems, commercial aviation systems and aero structures, land vehicle systems, electro-optic and countermeasures systems, homeland security systems, EW and signal intelligence systems, and various commercial activities, as well as command, control, communications, computer, and intelligence and cyber systems. The company also provides a range of support services fo r its defense systems and products. Elbit Systems Ltd. markets its systems and products as a prime contractor or subcontractor to various governments and defense contractors. The company was founded in 1966 and is based in Haifa, Israel.
Advisors' Opinion:- [By Rich Smith]
What it means to investors
If the A-10's backers in Congress are successful in saving the A-10, that would be good news for Northrop Grumman (NYSE: NOC ) , which has served as prime contractor for A-10 upgrading and maintenance work since 1987. (Israel's Elbit Systems (NASDAQ: ESLT ) actually owns the remains of Fairchild Republic, which built the A-10. But Northrop bought Fairchild's A-10 business.)
10 Best Low Price Stocks To Buy For 2014: Vertex Pharmaceuticals Incorporated(VRTX)
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Its products include telaprevir, a prescription medicine used for the treatment of patients with genotype 1 hepatitis C virus (HCV) infection; and Ivacaftor, a prescription medicine used for the treatment of cystic fibrosis. The company markets its products under the INCIVEK brand name in the United States and Canada; INCIVO brand in the United Kingdom, Germany, France, Sweden, Austria, Finland, Denmark, Switzerland, and Norway; KALYDECO brand in the United States; and TELAVIC brand in Japan. Its drug candidates comprise VX-222, a Phase II clinical trial drug candidate, and ALS-2200 and ALS-2158, a Phase I clinical trial drug candidates that are designed to inhibit the replication of HCV; VX-809 and VX-661, a Phase II clinical trial drug candidates that improve the function of defective cystic fibro sis; VX-509, a Phase II clinical trial drug candidate for the treatment of patients with rheumatoid arthritis and other immune-mediated inflammatory diseases; VX-765, a Phase II clinical trial drug for the treatment of epilepsy; and VX-787, an investigational drug candidate for the treatment of influenza A. The company was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion:- [By Keith Speights]
Vertical
How does a 60% gain in one day sound? The stock chart for Vertex Pharmaceuticals (NASDAQ: VRTX ) shows a nearly vertical line this week, as that one-day increase had shares jumping 53% for the week. - [By Ben Levisohn]
Vertex Pharmaceuticals (VRTX) popped 9.2% to $71.04 this week. The Street.com’s Adam Feuerstein predicted the Vertex’s cystic fibrosis drug would be successful in clinical trials.
- [By Sue Chang and Saumya Vaishampayan]
Vertex Pharmaceuticals Inc. (VRTX) �shares gained 3.9%. Geoff Meacham, an analyst at J.P. Morgan, said last week that he rates the drug maker�� stock at overweight due to opportunities for the company in the cystic fibrosis area.
- [By Ben Levisohn]
Stocks bucked their recent Monday weakness today as Visa (V), International Business Machines (IBM), United Technologies (UTX), Micron Technology (MU) and Vertex Pharmaceuticals (VRTX) gained. But your view of today likely depended on the index you were watching.
10 Best Low Price Stocks To Buy For 2014: Gyrodyne Company of America Inc.(GYRO)
Gyrodyne Company of America, Inc., a real estate investment trust (REIT), engages in the investment, acquisition, ownership, and management of a portfolio of medical office and industrial properties in the northeast region of the United States. The company also involves in the development of industrial and residential properties. It focuses on acquiring, developing, owning, leasing, and managing medical, commercial, and industrial real estate. The company has elected to be taxed as REIT under the Internal Revenue Code. As a REIT, it would not be subject to federal income tax purposes, provided that it distributes at least 90% of its taxable income to its shareholders. The company was founded in 1946 and is headquartered in St. James, New York.
Advisors' Opinion:- [By Geoff Gannon] >Syms (SYMSQ) where at some point the company�� entire value really depended on its balance sheet.
Obviously when looking at things like real estate you don�� go by what it says on the balance sheet. You try to find a note on depreciation that breaks out land, buildings, etc. And gives information about how the company depreciates its property.
And ��of course ��you look at the ��roperties��item in the 10-K. In the U.S., you then use the information you��e gathered to check county land records and things like that for more information about the property.
Generally, you want to:
路 Find out when the company bought the property
No comments:
Post a Comment